celz_10q.htm

0001477932-23-003347.txt : 20230512 0001477932-23-003347.hdr.sgml : 20230512 20230512163045 ACCESSION NUMBER: 0001477932-23-003347 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41120 FILM NUMBER: 23916310 BUSINESS ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 BUSINESS PHONE: 480-399-2822 MAIL ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 10-Q 1 celz_10q.htm FORM 10-Q celz_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 000-53500

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)

Nevada

87-0622284

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

211 E Osborn Road, Phoenix, AZ		85012
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (480) 399-2822

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CELZ		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of May 12, 2023, there were 14,076,238 shares of the registrant’s common stock outstanding.

		Page Number
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements

	Unaudited Condensed Consolidated Balance Sheets	3

	Unaudited Condensed Consolidated Statements of Operations	4

	Unaudited Condensed Consolidated Statements of Cash Flows	5

	Unaudited Condensed Consolidated Statements of Stockholder’ Equity (Deficit)	6

	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4.	Controls and Procedures	20

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	21

Item 6.	Exhibits	21

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2023			December 31, 2022
ASSETS
CURRENT ASSETS
Cash	$	9,516,203		$	8,320,519
Certificates of deposit		5,041,291			10,078,617
Inventory		10,194			10,194
Prepaids and other current assets		245,906			338,120
Total Current Assets		14,813,594			18,747,450

OTHER ASSETS
Other assets		3,281			3,281
Licenses, net of amortization		412,574			435,595
TOTAL ASSETS	$	15,229,449		$	19,186,326

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable	$	353,422		$	3,267,538
Accrued expenses		39,920			39,920
Advances from related party		14,194			14,194
Total Current Liabilities		407,536			3,321,652

TOTAL LIABILITIES		407,536			3,321,652

Commitments and contingencies

STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000,000 shares authorized; 14,076,246 and 14,076,246 issued and 14,076,238 and 14,076,238 outstanding at March 31, 2023 and December 31, 2022, respectively		14,077			14,077
Additional paid-in capital		69,671,617			69,662,455
Accumulated deficit		(54,863,781	)		(53,811,858	)
TOTAL STOCKHOLDERS’ EQUITY		14,821,913			15,864,674

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	15,229,449		$	19,186,326

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended March 31, 2023			For the Three Months Ended March 31, 2022

Revenues	$	-		$	15,000

Cost of revenues		-			6,791

Gross profit		-			8,209

OPERATING EXPENSES
Research and development		319,029			10,000
Selling, general and administrative		771,020			1,130,057
Amortization of patent costs		23,021			23,021
TOTAL EXPENSES		1,113,070			1,163,078

Operating loss		(1,113,070	)		(1,154,869	)

OTHER INCOME/(EXPENSE)
Interest expense		(50	)		-
Interest income		61,197			-
Total other income/(expense)		61,147			-

LOSS BEFORE PROVISION FOR INCOME TAXES		(1,051,923	)		(1,154,869	)

Provision for income taxes		-			-

NET LOSS	$	(1,051,923	)	$	(1,154,869	)

NET LOSS PER SHARE - BASIC AND DILUTED	$	(0.07	)	$	(0.18	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		14,076,238			6,454,015

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Three Months Ended March 31, 2023			For the Three Months Ended March 31, 2022

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,051,923	)	$	(1,154,869	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Stock-based compensation		9,162			41,360
Amortization		23,021			23,021
Changes in assets and liabilities:
Accounts receivable		-			2,485
Inventory		-			(3,284	)
Prepaids and other current assets		92,214			(64,960	)
Accounts payable		(2,914,116	)		(426,181	)
Accrued expenses		-			5,535
Net cash used in operating activities		(3,841,642	)		(1,576,893	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Redemptions of certificates of deposit		5,037,326			-
Net cash used in investing activities		5,037,326			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities		-			-

NET INCREASE (DECREASE) IN CASH		1,195,684			(1,576,893	)
BEGINNING CASH BALANCE		8,320,519			10,723,870
ENDING CASH BALANCE	$	9,516,203		$	9,146,977

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	50		$	9,186
Cash payments for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of management fees and patent liability into common stock	$	-		$	250,000

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(DEFICIT)

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		in Capital		Deficit			Equity
December 31, 2022		-	$	-		-	$	-		-	$	-		14,076,238	$	14,077	$	69,662,455	$	(53,811,858	)	$	15,864,674

Stock-based compensation		-		-		-		-		-		-		-		-		9,162		-			9,162
Net loss		-		-		-		-		-		-		-		-		-		(1,051,923	)		(1,051,923	)

March 31, 2023		-	$	-		-	$	-		-	$	-		14,076,238	$	14,077		69,671,617	$	(54,863,781	)	$	14,821,913

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		in Capital		Deficit			Equity
December 31, 2021		-	$	-		-	$	-		-	$	-		6,338,864	$	6,339	$	53,879,215	$	(43,667,814	)	$	10,217,740

Common stock issued for related party patent liabilities		-		-		-		-		-		-		181,818		182		249,818		-			250,000
Stock-based compensation		-		-		-		-		-		-		-		-		41,360		-			41,360
Net loss		-		-		-		-		-		-		-		-		-		(1,154,869	)		(1,154,869	)

March 31, 2022		-	$	-		-	$	-		-	$	-		6,520,682	$	6,521	$	54,170,393	$	(44,822,683	)	$	9,354,231

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2023

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities.

The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively.

In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

Use of Estimates – The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.

Table of Contents

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains a minimal level of inventory and requires nearly all of its customers to pre-pay, there is no risk to receivables or inventory write-downs. The Company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period The Company intends to actively monitor the bid price for our common stock between now and July 3, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future.

Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.

Table of Contents

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.

Payments received for which the earnings process is not yet complete are deferred. As of March 31, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of March 31, 2022.

Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of March 31, 2023, the Company’s balance exceeded the limit at both institutions.

Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023, and 2022, the Company had no outstanding derivative liabilities.

Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three-months ended March 31, 2023, the Company had 111,824 options and 22,849,266 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. The Company excluded 111,824 options and 6,604,820 warrants from the computation of diluted net income per share for the three-months ended March 31, 2022, as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.

Table of Contents

Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.

Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

NOTE 2 – LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 431,111 shares of CMTH restricted common stock valued at $100,000. CMH holds a significant amount of the Company’s common stock. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $2,493 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $28,521. The Company expects to amortize $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a university. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of March 31, 2023, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $293 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $2,912. The Company expects to amortize approximately $1,172 annually through 2025 related to the patent costs.

Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

Table of Contents

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2021, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2020.

The patent expires on May 19, 2027, and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $2,500 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the initial patent license was $42,500. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

The Company has elected to amortize the additional $300,000 associated with the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $144,889. The Company expects to amortize approximately $46,000 annually through 2026 related to the patent costs.

ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor, and as documented in standard operating procedures (SOPs) and other written documentation to augment autologous cells. The terms of the agreement are as follows:

Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)

in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

Table of Contents

To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022.

The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $6,250 were recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $193,750. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.

The following is a rollforward of the Company’s licensing agreements for the three months-ended March 31, 2023.

	Assets		Accumulated Amortization

Balances at December 31, 2022	$	760,000	$	(324,405	)
Addition of new assets				-
Amortization		-		(23,021	)
Balances at March 31, 2023	$	760,000	$	(347,426	)

NOTE 3 – RELATED PARTY TRANSACTIONS

Jadi Cell License Agreement

On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022.

StemSpine Patent Purchase

The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2021 the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.

Table of Contents

NOTE 4 – DEBT

During the three-months ended March 31, 2023 and 2022 there were no debt issuances.

As of March 31, 2023, and 2022, the Company had no outstanding loans.

NOTE 5 – DERIVATIVE LIABILITIES

As-of March 31, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the three-months ended March 31, 2023 and 2022.

NOTE 6 – STOCK-BASED COMPENSATION

On September 6, 2021, the Company’s Board of Directors, and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 600,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants, and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success.

During the three-months ended March 31, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 111,187 shares of common stock with an exercise price of $1.69. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. As of March 31, 2023, future estimated stock-based compensation expected to be recorded was estimated to be $95,002. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below.

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

During the three-months ended March 31, 2023 and 2022, the fair market value of the options was insignificant to the financial statements.

Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies.

There were no options issued during the three-months ended March 31, 2023, and 111,817 options issued during the three-months ended March 31, 2022.

Table of Contents

Option activity for the three-months ended March 31, 2023, consists of the following:

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		111,824	$	2.14		9.11
Issued		-		-		-
Exercised		-		-		-
Expired		-		-		-
Outstanding, March 31, 2023		111,824	$	2.14		8.86
Vested, March 31, 2023		55,909	$	2.14		8.86

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements.

See Note 7 for warrant rollforward.

NOTE 7 – STOCKHOLDERS’ EQUITY

May 2022 Private Offering

On May 3, 2022, the Company completed the sale of (i) 2,991,669 shares of common stock, and pre-funded warrants to purchase 4,563,887 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of common stock (the “Common Warrants”), at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

The Common Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants did not have an expiration date and had an exercise price of $0.0001 per share. As of March 31, 2023, all of the Pre-Funded Warrants had been exercised.

The Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, did not embody an obligation for the Company to repurchase its shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants did not provide any guarantee of value or return.

Roth Capital Partners (“Roth”) acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 1,133,333 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers.

Table of Contents

Warrants

In connection with our May 2022 private offering, we issued pre-funded warrants to purchase 4,563,887 shares of common stock and accompanying warrants to purchase 16,244,445 shares of common stock at a price of $2.00 per share.

Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows:

	Range of Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.83

As of March 31, 2023, and 2022, warrants to purchase 22,849,266 and 6,604,820 shares of common stock were outstanding respectively.

Warrant activity for the three-months ended March 31, 2023 consists of the following:

	Warrants		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		22,849,266	$	2.66		4.22
Issuances		-		-		-
Exercises		-		-		-
Outstanding, March 31, 2023		22,849,266	$	2.66		3.97

NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

On December 15, 2022, the Company purchased a set of components referred to as “research tools” for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with, pursuant to the terms of an Asset Purchase Agreement between the Company and Narkeshyo. Some of the acquired research tools were originally developed by the former director and current consultant. Under the terms of the agreement, the Company made an initial payment to Narkeshyo in the amount of $2,000,000 upon execution of the agreement, with the remaining amounts to be paid at various times through March 15, 2023, which were made as scheduled. Upon execution of the agreement, the Company recorded $5,000,000 as research and development expenses.

The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products. This acquisition of the research tools aligned with the Company’s priority of advancing and augmenting its suite of cGMP (Current Good Manufacturing Practices) cellular therapy products. The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development. The information contained in the research tools will not only be used to support and fast-track the Company’s regulatory filings (such as IND, NDA, ANDA and export applications), but also, provide clinical and regulatory support to potential partners and collaborators without having to divulge trade secrets and know-how.

A third-party analysis of this acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company’s research and development expenses over the long term.

Table of Contents

The purchased tools included (but were not limited to):

	·	Toxicology
	·	Screening
	·	Preclinical Testing
	·	Assays
	·	Authorization
	·	Tools of Biological Transaction
	·	Tools of Intellectual Property

NOTE 9 – SUBSEQUENT EVENTS

There were no material subsequent events during this period.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022, and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Table of Contents

Overview

We are a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:

Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in May 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc. nor AlloCelz LLC have commenced commercial activities.

We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem^® and FemCelz^® kits are currently available through physicians at eight locations in the United States.

In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

In June 2022, we signed an agreement with Greenstone Biosciences Inc. for the development of a human induced pluripotent stem cell (iPSC) pipeline for our ImmCelz® platform. This project was identified as iPScelz™. The efforts by Greenstone Biosciences Inc. are expected to complement and expand our current work on novel therapeutic cell lines.

In October 2022, we announced the development of our AlloStem™ Clinical Cell Line, a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File. We believe we will able to use this cell line for many of our programs, including our ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, CELZ-201 for Type 1 diabetes, StemSpine® for lower back pain, and IPScelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences.

In November 2022, we announced that the FDA had cleared the Company’s CELZ-201 Investigational New Drug (IND) application for the treatment of Type 1 Diabetes, which will allow us to begin a Phase I/II clinical trial. The primary objective of the study will be to evaluate CELZ-201 in patients with newly diagnosed Type 1 Diabetes. Patient recruitment is expected to begin in 2023.

In February 2023, the Company reported positive three-year follow-up data for its StemSpine® pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

In March 2023, the Company announced that it filed an application with the FDA to receive Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz®(CELZ-100) platform, and in April 2023, the Company reported positive one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type 2 Diabetes without any serious adverse effects reported

In addition to our clinical research efforts, we are currently seeking to expand the commercial sale and use of our CaverStem® and FemCelz® products by physicians in the United States.

Results of Operations – For the Three-month Periods Ended March 31, 2023, and 2022

Table of Contents

Gross Revenue. We generated no revenue for the three-months ended March 31, 2023, in comparison with $15,000 for the comparable period a year ago. The pause in sales reflects the Company’s re-evaluation of marketing and distribution options to generate improved sales of the Caverstem and FemCelz procedures.

Cost of Goods Sold. We generated no cost of goods sold for the three-months ended March 31, 2023, in comparison with $6,791 for the comparable period a year ago. The decrease is due to the reduction in sales.

Gross Profit/(Loss). We generated $0 in gross profit for the three-months ended March 31, 2023, in comparison with $8,209 in gross profit for the comparable period a year ago.

Selling, General and Administrative Expenses. General and administrative expenses for the three-months ended March 31, 2023, totaled $771,020, in comparison with $1,130,057 for the comparable period a year ago. The decrease of $359,037, or 32% is primarily due to a decrease of $83,422 in D&O insurance, $118,000 in consulting services, and $40,942 in marketing.

Amortization Expenses. Amortization expenses for the three-month periods ended March 31, 2023 and 2022, totaled $23,021.

Research and Development Expenses. Research and development expenses for the three-months ended March 31, 2023, totaled $319,029 in comparison to $10,000 for the comparable period a year ago. The increase of $309,029, or 3,090% was due to $259,029 of trial-related expenses associated with our CELZ-201 Phase I/II diabetes trial and $60,000 in research consulting expenses associated with progressing our multiple programs.

Operating Loss. For the reasons stated above, our operating loss for the three-months ended March 31, 2023, was $1,113,070 in comparison with $1,154,869 for the comparable period a year ago.

Other Income. Other income for the three-months ended March 31, 2023, totaled $61,147 in comparison with $0 for the comparable period a year ago. The increased income of $61,147 is due to an increase of $61,197 in interest income associated with $5,000,000 in short-term certificates of deposit.

Net Income/Loss. For the reasons stated above, our net loss for the three-months ended March 31, 2023, was $1,051,943 in comparison with a net loss of $1,154,869 for the comparable period a year ago.

Liquidity and Capital Resources

As of March 31, 2023, we had $14,557,494 of available cash and certificates of deposit and positive working capital of approximately $14,406,058. In comparison, as of December 31, 2022, we had $18,399,136 of available cash and positive working capital of $15,425,798.

On May 3, 2022 we received gross proceeds of $17,000,000, before deducting placement agent fees and expenses, upon the closing of an unregistered sale of equity securities of (i) 2,991,669 shares of our common stock and pre-funded warrants to purchase 4,563,887 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of common stock at an exercise price of $2.00 per share (“Warrants”), at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Warrant to a group of institutional investors (the “Purchasers”). The Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants do not expire and had an exercise price of $0.0001 per share. Roth Capital Partners acted as sole placement agent for the offering. We paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 1,133,333 shares of common stock with the same terms as the common warrants issued to the purchasers. Pursuant to the Purchase Agreement, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares of Common Stock issued in the offering and the shares of Common Stock underlying the Warrants and Pre-Funded Warrants. On May 10, 2022, we filed a Form S-3 registration statement to register the shares, Warrants and Pre-Funded Warrants for resale. The registration went effective on May 19, 2022, fulfilling our contractual obligation. From June through July 2022, all of the Pre-Funded Warrants were exercised for shares of common stock.

Table of Contents

Cash Flows

Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $3,841,642 for the three months-ended March 31, 2023, in comparison to $1,576,893 for the comparable period a year ago, an increase of $2,264,749 or 142%. The increase in cash used in operations was primarily related to $3,000,000 in cash payments related to the purchase of research tools referenced in Note 8.

Net Cash Received in Investing Activities. Cash received in investing activities was $5,037,326 for the three-months ended March 31, 2023, related to redemptions of $5,000,000 in certificates of deposit in comparison to $0 for the three-months ended March 31, 2022.

Net Cash from Financing Activities.

There were no cash proceeds or expenditures from financing activities during the three-months ended March 31, 2023, and 2022.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles accepted in the United States. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2023.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Description of Material Weaknesses

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of a company’s financial reporting. In connection with the preparation and audit of the Company’s financial statements for the year ended the December 31, 2022, management identified the following deficiencies that alone or in combination, represent material weaknesses in internal control over financial reporting, the material weaknesses are still present for the three months ended March 31, 2023 and are as follows:

·	Previously, we failed to adequately disclose the transaction in which we purchased research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with.

·	During the year ended December 31, 2022, we did not sufficiently segregate the duties of our officers.

We intend to remediate the deficiencies described above, and take such other action as we deem appropriate to further strengthen our internal control over financial reporting. We are currently in the process of establishing additional review and procedure controls. For instance, subsequent to quarter end we have implemented a policy whereby disbursements over a certain dollar threshold require dual authorization for processing and payment. The Company expects to remediate the deficiencies and obtain operating effectiveness over the next few quarters. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

In October 2022, we terminated an employee for cause. Subsequent to the termination, in December 2022, the employee brought claims against us for breach of contract, wrongful termination and related claims in the Superior Court of the State California (Orange County). The parties have submitted the action for arbitration before JAMS, where it is now pending.

Item 6. Exhibits

Exhibits
3.1.1		Articles of Incorporation of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
3.1.2		Certificate of Designation of the Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2018).
3.1.3		Certificate of Amendment to Certificate of Designation of the Series A Preferred Stock Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on March 11, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.4		Certificate of Designation of the Series B Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.5		Certificate of Designation of the Series C Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2021).
3.1.6		Certificate of Amendment to Articles of Incorporation Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.7		Certificate of Withdrawal of Certificate of Designation of Series B Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).

Table of Contents

3.1.8		Certificate of Withdrawal of Certificate of Designation of Series C Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.9		Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on November 8, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2021).
3.2		Bylaws of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.2 to the Company’s Form 10 filed with the Securities and Exchange Commission on November 18, 2008).
4.1		Form of Public Warrant issued in December 7, 2021 public offering (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 23, 2021).
4.2		Underwriter’s Warrant issued to Roth Capital Partners, LLC dated December 7, 2021 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).
4.3		Form of 15% Original Issue Discount Senior Note Due February 11, 2022 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2021).
4.4		Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of August 9, 2021 between Creative Medical Technology Holdings, Inc. and the purchasers named therein (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2021).
10.1		Management Reimbursement Agreement dated November 17, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Technologies, Inc. (incorporated by reference to Exhibit 10.27 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
10.2		Patent Purchase Agreement dated May 17, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Health, Inc. (incorporated by reference to Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
10.3		Amendment and Waiver to Patent Purchase Agreement dated November 14, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Health, Inc. (incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
10.4		Agreement dated December 28, 2020, between Jadi Cell LLC and ImmCelz, Inc. (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 28, 2021).
10.5		Warrant Agency Agreement between Creative Medical Technology Holdings, Inc. and vStock Transfer LLC dated December 7, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).
10.6†		2021 Equity Incentive Plan (incorporated by reference to Appendix B to the Company’s Information Statement on Schedule 14C filed with the Securities and Exchange Commission on September 24, 2021).
10.7†		Employment Agreement between Creative Medical Technology Holdings, Inc. and Timothy Warbington, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).
10.8†		Employment Agreement between Creative Medical Technology Holdings, Inc. Company and Donald Dickerson, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).
31.1		Rule 13a-14(a)/15d-14a(a) Certification of Principal Executive Officer*
31.2		Rule 13a-14(a)/15d-14a(a) Certification of Principal Financial Officer*
32.1		Section 1350 Certification of Principal Executive Officer *
32.2		Section 1350 Certification of Principal Financial Officer *
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

________

† Management contract or compensatory plan or arrangement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Creative Medical Technology Holdings, Inc.

Date: May 12, 2023	By	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: May 12, 2023	By	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 celz_ex311.htm CERTIFICATION celz_ex311.htm

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Timothy Warbington, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended March 31, 2023;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2023

By:

/s/ Timothy Warbington

Timothy Warbington

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 celz_ex312.htm CERTIFICATION celz_ex312.htm

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Donald Dickerson, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended March 31, 2023;

b)

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2023

By:

/s/ Donald Dickerson

Donald Dickerson

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 celz_ex321.htm CERTIFICATION celz_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Timothy Warbington, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1.

Such Quarterly Report on Form 10-Q for the period ended March 31, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in such Quarterly Report on Form 10-Q for the period ended March 31, 2023 fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc

Date: May 12, 2023

By:

/s/ Timothy Warbington

Timothy Warbington

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 celz_ex322.htm CERTIFICATION celz_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Donald Dickerson, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1.

Such Quarterly Report on Form 10-Q for the period ended March 31, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in such Quarterly Report on Form 10-Q for the period ended March 31, 2023, fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc.

Date: May 12, 2023

By:

/s/ Donald Dickerson

Donald Dickerson

Chief Financial Officer

(Principal Financial Officer)

EX-101.SCH 6 celz-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - STOCKBASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - LICENSING AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - STOCKBASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - LICENSING AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - STOCKBASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - STOCKBASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 celz-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash Certificates of deposit Inventory Prepaids and other current assets Total Current Assets [Assets, Current] OTHER ASSETS Other assets Licenses, net of amortization TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Advances from related party Total Current Liabilities [Liabilities, Current] TOTAL LIABILITIES [Liabilities] Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, $0.001 par value, 50,000,000,000 shares authorized; 14,076,246 and 14,076,246 issued and 14,076,238 and 14,076,238 outstanding at March 31, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Cost of revenues Gross profit [Gross Profit] OPERATING EXPENSES Research and development Selling, general and administrative Amortization of patent costs TOTAL EXPENSES [Operating Expenses] Operating loss [Operating Income (Loss)] OTHER INCOME/(EXPENSE) Interest expense [Interest Expense] Interest income Total other income/(expense) [Nonoperating Income (Expense)] LOSS BEFORE PROVISION FOR INCOME TAXES [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Provision for income taxes NET LOSS [Net Income (Loss) Attributable to Parent] NET LOSS PER SHARE - BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Amortization Changes in assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Inventory [Increase (Decrease) in Inventories] Prepaids and other current assets [Increase (Decrease) in Prepaid Expense and Other Assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Redemptions of certificates of deposit Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] BEGINNING CASH BALANCE [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] ENDING CASH BALANCE SUPPLEMENTAL CASH FLOW INFORMATION: Cash payments for interest Cash payments for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of management fees and patent liability into common stock UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Equity Components [Axis] Series A, Preferred Stock Series B, Preferred Stock Series C, Preferred Stock Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Common stock issued for related party patent liabilities, shares Common stock issued for related party patent liabilities, amount Stock-based compensation [Stock-based compensation] Net loss Balance, shares Balance, amount ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization And Summary Of Significant Accounting Policies LICENSING AGREEMENTS Licensing Agreements RELATED PARTY TRANSACTIONS Related Party Transactions DEBT Debt DERIVATIVE LIABILITIES Derivative Liabilities STOCKBASED COMPENSATION Stock-based Compensation STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE [SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE] SUBSEQUENT EVENTS Subsequent Events Organization Use Of Estimates Basis Of Presentation Risks And Uncertainties Revenue Concentration Risks Fair Value Of Financial Instruments Basic and Diluted Loss Per Share Cash Equivalents Inventories Recent Accounting Pronouncements Schedule Of Licensing Agreements Schedule Of Warrants Schedule Of Stock Option Activity Schedule of stockholders deficit Schedule of warrant activity Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Options [Member] Warrants [Member] FDIC insured amount Deferred revenue Anti-dilutive Securities Excluded From Computation Of Earning Per Share Assets Beginning Balance [Beginning Balance] Amortization [Amortization] Ending balance [Ending balance] Accumulated Amortization Accumulated Amortization, Beginning Balance [Accumulated Amortization, Beginning Balance] Addition of new assets Amortization [Amortization 1] Accumulated Amortization, Ending Balance [Accumulated Amortization, Ending Balance] Subsidiary Sale Of Stock Axis Plan Name Axis Subsegments Axis Financial Instrument Axis EX-101.CAL 8 celz-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 celz-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 celz-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 11 celz_10qimg1.jpg begin 644 celz_10qimg1.jpg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�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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 12, 2023
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		14,076,238
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-53500
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	87-0622284
Entity Interactive Data Current	Yes
Entity Address Address Line 1	211 E Osborn Road
Entity Address City Or Town	Phoenix
Entity Address State Or Province	AZ
Entity Address Postal Zip Code	85012
City Area Code	480
Local Phone Number	399-2822
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CELZ
Security Exchange Name	NASDAQ

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 9,516,203	$ 8,320,519
Certificates of deposit	5,041,291	10,078,617
Inventory	10,194	10,194
Prepaids and other current assets	245,906	338,120
Total Current Assets	14,813,594	18,747,450
OTHER ASSETS
Other assets	3,281	3,281
Licenses, net of amortization	412,574	435,595
TOTAL ASSETS	15,229,449	19,186,326
CURRENT LIABILITIES
Accounts payable	353,422	3,267,538
Accrued expenses	39,920	39,920
Advances from related party	14,194	14,194
Total Current Liabilities	407,536	3,321,652
TOTAL LIABILITIES	407,536	3,321,652
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 50,000,000,000 shares authorized; 14,076,246 and 14,076,246 issued and 14,076,238 and 14,076,238 outstanding at March 31, 2023 and December 31, 2022, respectively	14,077	14,077
Additional paid-in capital	69,671,617	69,662,455
Accumulated deficit	(54,863,781)	(53,811,858)
TOTAL STOCKHOLDERS' EQUITY	14,821,913	15,864,674
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 15,229,449	$ 19,186,326

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000,000	50,000,000,000
Common Stock, Shares Issued	14,076,246	14,076,246
Common Stock, Shares Outstanding	14,076,238	14,076,238

XML 15 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 15,000
Cost of revenues	0	6,791
Gross profit	0	8,209
OPERATING EXPENSES
Research and development	319,029	10,000
Selling, general and administrative	771,020	1,130,057
Amortization of patent costs	23,021	23,021
TOTAL EXPENSES	1,113,070	1,163,078
Operating loss	(1,113,070)	(1,154,869)
OTHER INCOME/(EXPENSE)
Interest expense	(50)	0
Interest income	61,197	0
Total other income/(expense)	61,147	0
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,051,923)	(1,154,869)
Provision for income taxes	0	0
NET LOSS	$ (1,051,923)	$ (1,154,869)
NET LOSS PER SHARE - BASIC AND DILUTED	$ (0.07)	$ (0.18)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	14,076,238	6,454,015

XML 16 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,051,923)	$ (1,154,869)
net cash used in operating activities:
Stock-based compensation	9,162	41,360
Amortization	23,021	23,021
Changes in assets and liabilities:
Accounts receivable	0	2,485
Inventory	0	(3,284)
Prepaids and other current assets	92,214	(64,960)
Accounts payable	(2,914,116)	(426,181)
Accrued expenses	0	5,535
Net cash used in operating activities	(3,841,642)	(1,576,893)
CASH FLOWS FROM INVESTING ACTIVITIES:
Redemptions of certificates of deposit	5,037,326	0
Net cash used in investing activities	5,037,326	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash provided by financing activities	0	0
NET INCREASE (DECREASE) IN CASH	1,195,684	(1,576,893)
BEGINNING CASH BALANCE	8,320,519	10,723,870
ENDING CASH BALANCE	9,516,203	9,146,977
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	50	9,186
Cash payments for income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of management fees and patent liability into common stock	$ 0	$ 250,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Series A, Preferred Stock	Series B, Preferred Stock	Series C, Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021					6,338,864
Balance, amount at Dec. 31, 2021	$ 10,217,740	$ 0	$ 0	$ 0	$ 6,339	$ 53,879,215	$ (43,667,814)
Common stock issued for related party patent liabilities, shares					181,818
Common stock issued for related party patent liabilities, amount	250,000	0	0	0	$ 182	249,818	0
Stock-based compensation	41,360	0	0	0	0	41,360	0
Net loss	(1,154,869)	0	0	0	$ 0	0	(1,154,869)
Balance, shares at Mar. 31, 2022					6,520,682
Balance, amount at Mar. 31, 2022	9,354,231	0	0	0	$ 6,521	54,170,393	(44,822,683)
Balance, shares at Dec. 31, 2022					14,076,238
Balance, amount at Dec. 31, 2022	15,864,674	0	0	0	$ 14,077	69,662,455	(53,811,858)
Stock-based compensation	9,162	0	0	0	0	9,162	0
Net loss	(1,051,923)	0	0	0	$ 0	0	(1,051,923)
Balance, shares at Mar. 31, 2023					14,076,238
Balance, amount at Mar. 31, 2023	$ 14,821,913	$ 0	$ 0	$ 0	$ 14,077	$ 69,671,617	$ (54,863,781)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization And Summary Of Significant Accounting Policies

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.

XML 19 R8.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS

3 Months Ended

Mar. 31, 2023

LICENSING AGREEMENTS

Licensing Agreements

NOTE 2 – LICENSING AGREEMENTS

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

The following is a rollforward of the Company’s licensing agreements for the three months-ended March 31, 2023.

	Assets		Accumulated Amortization

Balances at December 31, 2022	$	760,000	$	(324,405	)
Addition of new assets				-
Amortization		-		(23,021	)
Balances at March 31, 2023	$	760,000	$	(347,426	)

XML 20 R9.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2023

RELATED PARTY TRANSACTIONS

Related Party Transactions

NOTE 3 – RELATED PARTY TRANSACTIONS

Jadi Cell License Agreement

StemSpine Patent Purchase

XML 21 R10.htm IDEA: XBRL DOCUMENT

DEBT

3 Months Ended

Mar. 31, 2023

DEBT

Debt

NOTE 4 – DEBT

During the three-months ended March 31, 2023 and 2022 there were no debt issuances.

As of March 31, 2023, and 2022, the Company had no outstanding loans.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

3 Months Ended

Mar. 31, 2023

DERIVATIVE LIABILITIES

Derivative Liabilities

NOTE 5 – DERIVATIVE LIABILITIES

As-of March 31, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the three-months ended March 31, 2023 and 2022.

XML 23 R12.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION

3 Months Ended

Mar. 31, 2023

STOCKBASED COMPENSATION

Stock-based Compensation

NOTE 6 – STOCK-BASED COMPENSATION

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

During the three-months ended March 31, 2023 and 2022, the fair market value of the options was insignificant to the financial statements.

There were no options issued during the three-months ended March 31, 2023, and 111,817 options issued during the three-months ended March 31, 2022.

Option activity for the three-months ended March 31, 2023, consists of the following:

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		111,824	$	2.14		9.11
Issued		-		-		-
Exercised		-		-		-
Expired		-		-		-
Outstanding, March 31, 2023		111,824	$	2.14		8.86
Vested, March 31, 2023		55,909	$	2.14		8.86

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements.

See Note 7 for warrant rollforward.

XML 24 R13.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

3 Months Ended

Mar. 31, 2023

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

May 2022 Private Offering

Warrants

Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows:

	Range of Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.83

As of March 31, 2023, and 2022, warrants to purchase 22,849,266 and 6,604,820 shares of common stock were outstanding respectively.

Warrant activity for the three-months ended March 31, 2023 consists of the following:

	Warrants		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		22,849,266	$	2.66		4.22
Issuances		-		-		-
Exercises		-		-		-
Outstanding, March 31, 2023		22,849,266	$	2.66		3.97

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

3 Months Ended

Mar. 31, 2023

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

The purchased tools included (but were not limited to):

	·	Toxicology
	·	Screening
	·	Preclinical Testing
	·	Assays
	·	Authorization
	·	Tools of Biological Transaction
	·	Tools of Intellectual Property

XML 26 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

SUBSEQUENT EVENTS

Subsequent Events

NOTE 9 – SUBSEQUENT EVENTS

There were no material subsequent events during this period.

XML 27 R16.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization	*Organization* - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.
Use Of Estimates	Use of Estimates – The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basis Of Presentation	*Basis of Presentation* – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Risks And Uncertainties	*Risks and Uncertainties* - The Company has a limited operating history and has generated minimal revenues from its operations. On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains a minimal level of inventory and requires nearly all of its customers to pre-pay, there is no risk to receivables or inventory write-downs. The Company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period The Company intends to actively monitor the bid price for our common stock between now and July 3, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.
Revenue	Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of March 31, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of March 31, 2022.
Concentration Risks	*Concentration Risks* – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of March 31, 2023, the Company’s balance exceeded the limit at both institutions.
Fair Value Of Financial Instruments	Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023, and 2022, the Company had no outstanding derivative liabilities.
Basic and Diluted Loss Per Share	*Basic and Diluted Income (Loss) Per Share* – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three-months ended March 31, 2023, the Company had 111,824 options and 22,849,266 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. The Company excluded 111,824 options and 6,604,820 warrants from the computation of diluted net income per share for the three-months ended March 31, 2022, as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.
Cash Equivalents	Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.
Inventories	*Inventories* – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Tables)

3 Months Ended

Mar. 31, 2023

LICENSING AGREEMENTS

Schedule Of Licensing Agreements

	Assets		Accumulated Amortization

Balances at December 31, 2022	$	760,000	$	(324,405	)
Addition of new assets				-
Amortization		-		(23,021	)
Balances at March 31, 2023	$	760,000	$	(347,426	)

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2023

STOCKBASED COMPENSATION

Schedule Of Warrants

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

Schedule Of Stock Option Activity

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		111,824	$	2.14		9.11
Issued		-		-		-
Exercised		-		-		-
Expired		-		-		-
Outstanding, March 31, 2023		111,824	$	2.14		8.86
Vested, March 31, 2023		55,909	$	2.14		8.86

XML 30 R19.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Tables)

3 Months Ended

Mar. 31, 2023

STOCKHOLDERS EQUITY

Schedule of stockholders deficit

	Range of Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.83

Schedule of warrant activity

	Warrants		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		22,849,266	$	2.66		4.22
Issuances		-		-		-
Exercises		-		-		-
Outstanding, March 31, 2023		22,849,266	$	2.66		3.97

XML 31 R20.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
FDIC insured amount	$ 250,000
Deferred revenue	$ 40,000	$ 0
Options [Member]
Anti-dilutive Securities Excluded From Computation Of Earning Per Share	111,824	111,824
Warrants [Member]
Anti-dilutive Securities Excluded From Computation Of Earning Per Share	22,849,266	6,604,820

XML 32 R21.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details)	3 Months Ended
LICENSING AGREEMENTS (Details)	Mar. 31, 2023 USD ($)
Assets
Beginning Balance	$ 760,000
Amortization	0
Ending balance	760,000
Accumulated Amortization
Accumulated Amortization, Beginning Balance	(324,405)
Addition of new assets	0
Amortization	(23,021)
Accumulated Amortization, Ending Balance	$ (347,426)

XML 33 R22.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details Narrative) - USD ($)		1 Months Ended			3 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Dec. 12, 2020	Feb. 28, 2022	Dec. 28, 2020	May 17, 2017	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Feb. 02, 2016
License fees			$ 250,000
No of share Exchange										431,111
Restricted common stock										$ 100,000
obligation of the initial payment					$ 300,000		$ 300,000	$ 300,000	$ 300,000
common stock Issue	$ 6,667						84,656	89,286	133
Company paid CMH					50,000		$ 40,000	$ 50,000	$ 50,000
License agreement description			(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
Amortization expenses					23,021	$ 23,021
Number of share issuance of common stock to Jadi Cell		180,180
Carrying value of patent					28,521
Expected amount of amortization					9,972
Payments upon completion of the IRB clinical trial				$ 200,000
Payments in the event of commercialization of technology				300,000
Option [Member]
Initial payment	$ 100,000			100,000
Payments upon signing agreement with university for the initiation of an IRB clinical trial				100,000
Payments upon filing an IND with the FDA				100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial				200,000
Payments upon dosing of the first patient in Phase 3 clinical trial				$ 400,000
Percentage of discount on the basis of recent trading price				30.00%
Share price for two or more consecutive trading days				0.01
Option Warrant [Member]
Royalty payment percentage				5.00%
Non-royalty sublease income percentage				50.00%
License Agreement
Amortization expenses					293	293
Carrying value of patent					$ 2,912
Expiration period of finite-lived intangible assets					2026
Expected amount of amortization					$ 1,172
CMH [Member]
License fees					250,000
Amortization expenses					11,485	11,485
Carrying value of patent					$ 144,889
Expiration period of finite-lived intangible assets					2026
Expected annual amortization amount					$ 46,000
StemSpine LLC [Member]
Amortization expenses					2,500	2,500
Carrying value of patent					$ 42,500
Expiration period of finite-lived intangible assets					May 19, 2027
Expected amount of amortization					$ 10,000
Jadi Cell [Member]
Amortization expenses					6,250	$ 6,250
Carrying value of patent					193,750
Expected amount of amortization					$ 25,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended
	Dec. 28, 2020	May 17, 2017	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 12, 2020
Company Paid Cmh			$ 50,000		$ 40,000	$ 50,000	$ 50,000
Obligation Of The Initial Payment			$ 300,000		300,000	300,000	300,000
Common Stock Issued			14,076,246	14,076,246
StemSpine Patent Purchase [Member]
Company Paid Cmh		$ 50,000			40,000	50,000	50,000
Obligation Of The Initial Payment					$ 300,000	$ 300,000	$ 300,000
Common Stock Issued					84,656	89,286	133	6,667
Long-term Purchase Commitment, Amount		$ 100,000
Remaining portion of obligation paid in cash						$ 300,000
Jadi Cell License Agreement [Member]
License Fee	$ 250,000
Agreement Description	the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company
Common Stock Issued	180,180

XML 35 R24.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details)	3 Months Ended
STOCKBASED COMPENSATION (Details)	Mar. 31, 2023 $ / shares
Annual dividend yield	0.00%
Expected life (years)	5 years
Common stock price	$ 1.83
Option Warrant [Member]
Annual dividend yield	0.00%
Expected volatility	92.95%
Risk-free interest rate	0.81%
Expected life (years)	10 years
Common stock price	$ 1.69

XML 36 R25.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details 1) - Option [Member]	3 Months Ended
STOCKBASED COMPENSATION (Details 1) - Option [Member]	Mar. 31, 2023 $ / shares shares
Stock option, Outstanding at the begining	111,824
Stock option, Issued	0
Stock option, Outstanding at the end	111,824
Stock option, Vested	55,909
Weighted Average Exercise Price, Outstanding beginning \| $ / shares	$ 2.14
Weighted Average Exercise Price, Outstanding ending \| $ / shares	2.14
Weighted Average Exercise Price, Vested \| $ / shares	$ 2.14
Weighted Average Life Remaining, Outstanding beginning	9 years 1 month 9 days
Weighted Average Life Remaining, Outstanding ending	8 years 10 months 9 days
Weighted Average Life Remaining, Vested	8 years 10 months 9 days

XML 37 R26.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
STOCKBASED COMPENSATION (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Sep. 06, 2021
Common stock price	$ 1.83
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	111,187
Common stock price	$ 1.69
Stock option, Issued	0	111,817
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date
Future estimated stock-based compensation	$ 95,002
Employee Stock Options [Member] \| Black Scholes Method [Member]
Options vested, value	$ 145,525
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			600,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details)	3 Months Ended
STOCKHOLDERS EQUITY (Details)	Mar. 31, 2023 $ / shares
STOCKHOLDERS EQUITY
Annual dividend yield	0.00%
Expected life (years)	5 years
Risk-free interest rate	0.81%
Expected volatility	92.95%
Common stock price	$ 1.83

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details 1) - Warrants [Member]	3 Months Ended
STOCKHOLDERS EQUITY (Details 1) - Warrants [Member]	Mar. 31, 2023 $ / shares shares
Warrants, Outstanding Beginning Balance	22,849,266
Warrants, Issuances	0
Warrants, Exercises	0
Warrants, Outstanding Ending Balance	22,849,266
Weighted Average Exercise Price, Outstanding beginning \| $ / shares	$ 2.66
Weighted Average Exercise Price, Outstanding ending \| $ / shares	$ 2.66
Weighted Average Life Remaining, Outstanding Beginning	4 years 2 months 19 days
Weighted Average Life Remaining, Outstanding Ending	3 years 11 months 19 days

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	May 03, 2022	May 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Amendment description	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
Sale of shares of common stock	2,991,669
Pre-Funded Warrants Exercise price			$ 0.0001
Purchase of warrants shares	4,563,887
Purchase of Pre-Funded Warrant and related Common Warrant	15,111,112
Common warrants exercise price			$ 2.00
Combined offering price of Pre-Funded Warrant and related Common Warrant	$ 2.25
Roth Capital Partners [Member]
Paid placement agent fee			$ 1,360,000
Issued warrant to purchase shares of common stock			1,133,333
Private Offering [Member]
Warrants to purchase shares of common stock		4,563,887
Warrants [Member]
Warrants to purchase shares of common stock		16,244,445
Warrant exercise price		$ 2.00
Class of Warrant or Right, Outstanding			22,849,266	6,604,820

XML 41 R30.htm IDEA: XBRL DOCUMENT

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) - USD ($)		3 Months Ended
	Dec. 15, 2022	Mar. 31, 2023	Mar. 31, 2022
SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)
Research and development expenses	$ 5,000,000	$ 319,029	$ 10,000
Initial payment amount	$ 2,000,000

XML 42 celz_10q_htm.xml IDEA: XBRL DOCUMENT 0001187953 2023-01-01 2023-03-31 0001187953 2022-12-01 2022-12-15 0001187953 celz:WarrantsMember 2022-03-31 0001187953 celz:WarrantsMember 2023-03-31 0001187953 celz:RothCapitalPartnersMember 2023-01-01 2023-03-31 0001187953 2022-05-03 0001187953 celz:WarrantsMember 2022-05-01 2022-05-31 0001187953 celz:PrivateOfferingMember 2022-05-01 2022-05-31 0001187953 2022-05-01 2022-05-03 0001187953 celz:MinimumsssMember 2023-03-31 0001187953 celz:MinimumsssMember 2023-01-01 2023-03-31 0001187953 celz:MinimumsssMember 2022-12-31 0001187953 celz:BlackScholesMethodMember celz:EmployeeStockOptionssMember 2023-01-01 2023-03-31 0001187953 celz:EmployeeStockOptionssMember 2022-01-01 2022-03-31 0001187953 celz:EmployeeStockOptionssMember 2023-03-31 0001187953 celz:EmployeeStockOptionssMember 2023-01-01 2023-03-31 0001187953 celz:BoardOfDirectorsMember 2021-09-06 0001187953 us-gaap:OptionMember 2023-03-31 0001187953 us-gaap:OptionMember 2023-01-01 2023-03-31 0001187953 us-gaap:OptionMember 2022-12-31 0001187953 celz:WarrantssMember 2023-03-31 0001187953 celz:WarrantssMember 2023-01-01 2023-03-31 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-28 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-01 2020-12-28 0001187953 celz:StemSpinePatentPurchaseMember 2017-05-01 2017-05-17 0001187953 celz:StemSpinePatentPurchaseMember 2020-12-12 0001187953 celz:StemSpinePatentPurchaseMember 2021-09-30 0001187953 celz:StemSpinePatentPurchaseMember 2020-12-31 0001187953 celz:StemSpinePatentPurchaseMember 2021-01-31 0001187953 celz:StemSpinePatentPurchaseMember 2017-05-17 0001187953 2017-05-01 2017-05-17 0001187953 us-gaap:OptionMember 2020-12-01 2020-12-12 0001187953 us-gaap:OptionMember 2017-05-01 2017-05-17 0001187953 celz:JadiCellMember 2023-03-31 0001187953 celz:CMHMember 2023-03-31 0001187953 celz:StemSpineMember 2023-03-31 0001187953 celz:LicenseAgreementMember 2023-03-31 0001187953 celz:WarrantssMember 2017-05-01 2017-05-17 0001187953 2022-02-01 2022-02-28 0001187953 celz:JadiCellMember 2022-01-01 2022-03-31 0001187953 celz:JadiCellMember 2023-01-01 2023-03-31 0001187953 celz:StemSpineMember 2023-01-01 2023-03-31 0001187953 celz:LicenseAgreementMember 2023-01-01 2023-03-31 0001187953 celz:CMHMember 2022-01-01 2022-03-31 0001187953 celz:StemSpineMember 2022-01-01 2022-03-31 0001187953 celz:LicenseAgreementMember 2022-01-01 2022-03-31 0001187953 2020-12-12 0001187953 2021-01-31 0001187953 2021-09-30 0001187953 2020-12-31 0001187953 2016-02-02 0001187953 2020-12-01 2020-12-28 0001187953 celz:CMHMember 2023-01-01 2023-03-31 0001187953 celz:WarrantsMember 2022-01-01 2022-03-31 0001187953 celz:WarrantsMember 2023-01-01 2023-03-31 0001187953 celz:OptionsMember 2022-01-01 2022-03-31 0001187953 celz:OptionsMember 2023-01-01 2023-03-31 0001187953 us-gaap:RetainedEarningsMember 2023-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001187953 us-gaap:CommonStockMember 2023-03-31 0001187953 celz:SeriesCPreferredStocksMember 2023-03-31 0001187953 celz:SeriesBPreferredStocksMember 2023-03-31 0001187953 celz:SeriesAPreferredStocksMember 2023-03-31 0001187953 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001187953 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001187953 celz:SeriesCPreferredStocksMember 2023-01-01 2023-03-31 0001187953 celz:SeriesBPreferredStocksMember 2023-01-01 2023-03-31 0001187953 celz:SeriesAPreferredStocksMember 2023-01-01 2023-03-31 0001187953 us-gaap:RetainedEarningsMember 2022-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001187953 us-gaap:CommonStockMember 2022-12-31 0001187953 celz:SeriesCPreferredStocksMember 2022-12-31 0001187953 celz:SeriesBPreferredStocksMember 2022-12-31 0001187953 celz:SeriesAPreferredStocksMember 2022-12-31 0001187953 us-gaap:RetainedEarningsMember 2022-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001187953 us-gaap:CommonStockMember 2022-03-31 0001187953 celz:SeriesCPreferredStocksMember 2022-03-31 0001187953 celz:SeriesBPreferredStocksMember 2022-03-31 0001187953 celz:SeriesAPreferredStocksMember 2022-03-31 0001187953 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001187953 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001187953 celz:SeriesCPreferredStocksMember 2022-01-01 2022-03-31 0001187953 celz:SeriesBPreferredStocksMember 2022-01-01 2022-03-31 0001187953 celz:SeriesAPreferredStocksMember 2022-01-01 2022-03-31 0001187953 us-gaap:RetainedEarningsMember 2021-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001187953 us-gaap:CommonStockMember 2021-12-31 0001187953 celz:SeriesCPreferredStocksMember 2021-12-31 0001187953 celz:SeriesBPreferredStocksMember 2021-12-31 0001187953 celz:SeriesAPreferredStocksMember 2021-12-31 0001187953 2022-03-31 0001187953 2021-12-31 0001187953 2022-01-01 2022-03-31 0001187953 2022-12-31 0001187953 2023-03-31 0001187953 2023-05-12 iso4217:USD shares iso4217:USD shares pure 0001187953 false --12-31 Q1 2023

0.001

50000000000

293

2500

11485

6250

10-Q true 2023-03-31 false 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. NV 87-0622284 211 E Osborn Road Phoenix AZ 85012 480 399-2822 Common Stock, par value $0.001 per share CELZ NASDAQ Yes Yes Non-accelerated Filer true false false 14076238

9516203

8320519

5041291

10078617

10194

245906

338120

14813594

18747450

3281

412574

435595

15229449

19186326

353422

3267538

39920

14194

407536

3321652

407536

3321652

0.001

50000000000

14076246

14076238

14077

69671617

69662455

-54863781

-53811858

14821913

15864674

15229449

19186326

15000

6791

8209

319029

10000

771020

1130057

23021

1113070

1163078

-1113070

-1154869

61197

61147

-1051923

-1154869

-1051923

-1154869

-0.07 -0.18 14076238 6454015

1051923

1154869

9162

41360

23021

-2485

3284

-92214

64960

-2914116

-426181

5535

-3841642

-1576893

5037326 0

5037326

1195684

-1576893

8320519

10723870

9516203

9146977

9186

0 250000

14076238

14077

69662455

-53811858

15864674

0 0 0 0 9162 0 9162

-1051923

14076238

14077

69671617

-54863781

14821913

6338864

6339

53879215

-43667814

10217740

0 0 0 181818 182 249818 0 250000 0 0 0 0 41360 0 41360

-1154869

6520682

6521

54170393

-44822683

9354231

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. Use of Estimates – The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains a minimal level of inventory and requires nearly all of its customers to pre-pay, there is no risk to receivables or inventory write-downs. The Company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period The Company intends to actively monitor the bid price for our common stock between now and July 3, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of March 31, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of March 31, 2022. Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of March 31, 2023, the Company’s balance exceeded the limit at both institutions. Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023, and 2022, the Company had no outstanding derivative liabilities. Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three-months ended March 31, 2023, the Company had 111,824 options and 22,849,266 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. The Company excluded 111,824 options and 6,604,820 warrants from the computation of diluted net income per share for the three-months ended March 31, 2022, as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method. Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis. Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

Use of Estimates – The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains a minimal level of inventory and requires nearly all of its customers to pre-pay, there is no risk to receivables or inventory write-downs. The Company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period The Company intends to actively monitor the bid price for our common stock between now and July 3, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of March 31, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of March 31, 2022.

40000

Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of March 31, 2023, the Company’s balance exceeded the limit at both institutions.

250000

Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023, and 2022, the Company had no outstanding derivative liabilities.

Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the three-months ended March 31, 2023, the Company had 111,824 options and 22,849,266 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. The Company excluded 111,824 options and 6,604,820 warrants from the computation of diluted net income per share for the three-months ended March 31, 2022, as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.

111824

22849266

111824

6604820

Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.

Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

NOTE 2 – LICENSING AGREEMENTS ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 431,111 shares of CMTH restricted common stock valued at $100,000. CMH holds a significant amount of the Company’s common stock. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $2,493 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $28,521. The Company expects to amortize $9,972 annually through 2026 related to the patent costs. Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a university. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of March 31, 2023, no amounts are currently due to the University. The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $293 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $2,912. The Company expects to amortize approximately $1,172 annually through 2025 related to the patent costs. Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;vertical-align:top;">o </td><td style="vertical-align:top;">$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000, upon completion of the IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;">o </td><td style="vertical-align:top;">$100,000 upon filing an IND with the FDA.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$400,000 upon dosing the first patient in a Phase 3 clinical trial.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.</td></tr></tbody></table> The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2021, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2020. The patent expires on May 19, 2027, and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $2,500 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the initial patent license was $42,500. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs. The Company has elected to amortize the additional $300,000 associated with the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 was recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $144,889. The Company expects to amortize approximately $46,000 annually through 2026 related to the patent costs. ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor, and as documented in standard operating procedures (SOPs) and other written documentation to augment autologous cells. The terms of the agreement are as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”) </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.</td></tr></tbody></table>To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $6,250 were recorded for the three-months ended March 31, 2023, and 2022. As of March 31, 2023, the carrying value of the patent was $193,750. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs. The following is a rollforward of the Company’s licensing agreements for the three months-ended March 31, 2023. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(324,405 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23,021 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(347,426 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 431111 100000

28521

9972 2026 2026

293

2912

1172 100000 100000 200000 300000 100000 200000 400000 0.30 0.01 0.05 0.50 100000 50000 6667 50000 300000 133 40000 300000 84656 50000 300000 89286 300000 May 19, 2027

2500

42500

10000

11485

144889

46000 250000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement 250000 180180

6250

193750

25000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(324,405 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23,021 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(347,426 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 760000 -324405 0

-23021 760000 -347426

NOTE 3 – RELATED PARTY TRANSACTIONS Jadi Cell License Agreement On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022. StemSpine Patent Purchase The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2021 the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.

the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company 250000

180180

100000

50000 6667 50000 300000 133 40000 300000 84656 50000 300000 89286 300000

NOTE 4 – DEBT During the three-months ended March 31, 2023 and 2022 there were no debt issuances. As of March 31, 2023, and 2022, the Company had no outstanding loans.

NOTE 5 – DERIVATIVE LIABILITIES As-of March 31, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the three-months ended March 31, 2023 and 2022.

NOTE 6 – STOCK-BASED COMPENSATION On September 6, 2021, the Company’s Board of Directors, and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 600,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants, and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success. During the three-months ended March 31, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 111,187 shares of common stock with an exercise price of $1.69. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. As of March 31, 2023, future estimated stock-based compensation expected to be recorded was estimated to be $95,002. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the three-months ended March 31, 2023 and 2022, the fair market value of the options was insignificant to the financial statements. Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies. There were no options issued during the three-months ended March 31, 2023, and 111,817 options issued during the three-months ended March 31, 2022.Option activity for the three-months ended March 31, 2023, consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.11</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.86</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.86</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 7 for warrant rollforward.

600000

P10Y

111187

1.69

The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date

95002 145525 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

P10Y

0.0081

0.9295

1.69

111817

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.11</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.86</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,909</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.86</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

111824

2.14

P9Y1M9D

111824

2.14

P8Y10M9D

55909

2.14

P8Y10M9D

NOTE 7 – STOCKHOLDERS’ EQUITY May 2022 Private Offering On May 3, 2022, the Company completed the sale of (i) 2,991,669 shares of common stock, and pre-funded warrants to purchase 4,563,887 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of common stock (the “Common Warrants”), at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. The Common Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants did not have an expiration date and had an exercise price of $0.0001 per share. As of March 31, 2023, all of the Pre-Funded Warrants had been exercised. The Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, did not embody an obligation for the Company to repurchase its shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants did not provide any guarantee of value or return. Roth Capital Partners (“Roth”) acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 1,133,333 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers.Warrants In connection with our May 2022 private offering, we issued pre-funded warrants to purchase 4,563,887 shares of common stock and accompanying warrants to purchase 16,244,445 shares of common stock at a price of $2.00 per share. Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Range ofInputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.83</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of March 31, 2023, and 2022, warrants to purchase 22,849,266 and 6,604,820 shares of common stock were outstanding respectively. Warrant activity for the three-months ended March 31, 2023 consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,849,266</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.66</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.22</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,849,266</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.66</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.97</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2991669

4563887 15111112 2.25 pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder 2.00 0.0001 1360000 1133333 4563887 16244445 2.00

P5Y

0.0081

0.9295

1.83

22849266

6604820

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,849,266</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.66</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.22</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, March 31, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,849,266</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.66</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.97</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

22849266

2.66

P4Y2M19D

22849266

2.66

P3Y11M19D

NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE On December 15, 2022, the Company purchased a set of components referred to as “research tools” for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with, pursuant to the terms of an Asset Purchase Agreement between the Company and Narkeshyo. Some of the acquired research tools were originally developed by the former director and current consultant. Under the terms of the agreement, the Company made an initial payment to Narkeshyo in the amount of $2,000,000 upon execution of the agreement, with the remaining amounts to be paid at various times through March 15, 2023, which were made as scheduled. Upon execution of the agreement, the Company recorded $5,000,000 as research and development expenses. The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products. This acquisition of the research tools aligned with the Company’s priority of advancing and augmenting its suite of cGMP (Current Good Manufacturing Practices) cellular therapy products. The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development. The information contained in the research tools will not only be used to support and fast-track the Company’s regulatory filings (such as IND, NDA, ANDA and export applications), but also, provide clinical and regulatory support to potential partners and collaborators without having to divulge trade secrets and know-how. A third-party analysis of this acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company’s research and development expenses over the long term.The purchased tools included (but were not limited to): <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td>Toxicology </td></tr><tr style="height:15px"><td> </td><td>· </td><td>Screening</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Preclinical Testing</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Assays</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Authorization</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Tools of Biological Transaction</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Tools of Intellectual Property</td></tr></tbody></table> 2000000

5000000

NOTE 9 – SUBSEQUENT EVENTS There were no material subsequent events during this period.

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

Date: May 12, 2023	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 12, 2023	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)